You are currently viewing a new version of our website. To view the old version click .
Scientia Pharmaceutica
  • Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
  • Abstract
  • Open Access

16 April 2009

Targeted Delivery of siRNA to Tumor Cells with Designed Ankyrin Repeat Protein Nanocomplexes

and
1
Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria
2
Department of Pharmacology, University of Bern, Friedbühlstraße 49, 3010 Bern, Switzerland
*
Author to whom correspondence should be addressed.

Abstract

Specific delivery to tumors and efficient cellular uptake of nucleic acids are major challenges for gene-targeted cancer therapies. Tumor-targeted delivery using antibody fragments or immunoliposomes have already been demonstrated to enhance cellular uptake of nucleic acids by receptor-mediated endocytosis. Here we report the first use of an epithelial cell adhesion molecule (EpCAM)-specific designed ankyrin repeat protein (DARPin) as a carrier for siRNA. Designed ankyrin repeat proteins are a novel class of non-immunoglobulin binding proteins relying on the modularity of ankyrins. Their short length, high stability, and the lack of intramolecular cysteines facilitate proper folding, result in high-yield expression in E. coli, and allow engineering procedures usually not well tolerated by antibodies. A DARPin binding to EpCAM was derived from a designed protein library using ribosome display.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.